| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BMS-754807 | GDSC1000 | pan-cancer | AAC | 0.082 | 0.02 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.14 | 0.02 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.079 | 0.02 |
| mRNA | MK-2206 | GDSC1000 | pan-cancer | AAC | -0.088 | 0.02 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | -0.075 | 0.02 |
| mRNA | ABT-888 | CTRPv2 | pan-cancer | AAC | -0.085 | 0.02 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.081 | 0.02 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.12 | 0.02 |
| mRNA | Sunitinib | GDSC1000 | pan-cancer | AAC | -0.12 | 0.02 |
| mRNA | NSC-207895 | GDSC1000 | pan-cancer | AAC | -0.078 | 0.02 |